We are seeking a highly motivated individual with a 5 or more years of lab experience with a background in purification of small molecule libraries. Experience with gram scale chiral and achiral purification by HPLC and SFC is also desired.
This position will perform purifications of small molecule libraries by mass directed HPLC and scale up purification of synthetic starting materials or final compounds by (Supercritical Fluid Chromatography) SFC in support of our early drug discovery efforts at Nurix. The candidate requires the ability to develop custom purification methods using state of the art analytical and preparative scale equipment. This role also requires hands on experience in troubleshooting instrumentation to minimize downtime.
The candidate should have a strong desire to learn new techniques stay up to date with purification trends and interest to cross train team members. The ideal candidate will be self-driven, resourceful, very organized and focused, and enjoy working in the dynamic team environment here at Nurix.
Minimum qualifications include a B.S. or equivalent degree in chemistry, analytical chemistry or related field, with (2+) years of industrial experience, or a master’s degree in chemistry, biochemistry or a related field with (1+) years of industrial experience in purification of small molecules.
Fit with Nurix Culture and Values
- Strong team orientation; highly collaborative
- Solutions and results-oriented focus
- Hands-on approach; resourceful and open to diverse points of view
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.
Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.